🔥🐔 BizChicken 🐔🔥
Companies Similar to TransCode Therapeutics, Inc.
Sign Up Today!
Sign up for BizChicken and discover more about the corporations around you.
Capricor Therapeutics, Inc.
CAP-1002
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company specializing in developing transformative cell and exosome-based therapeutics aimed at treating and preventing a range of diseases and disorders. Their lead candidate, CAP-1002, is designed for Duchenne muscular dystrophy and cytokine storm interventions.
About | Leadership | Directors | About | About | Contact | Careers | About | About | About | About
Symbol: CAPR
Recent Price: $13.76
Industry: Biotechnology
CEO: Dr. Linda Marbán Ph.D.
Sector: Healthcare
Employees: 101
Address: 10865 Road to the Cure, San Diego, CA 92121
Phone: 310 358 3200
Leadership
- Linda Marbán, Ph.D., Chief Executive Officer and Director
- Kristi A. H. Elliott, Ph.D., Chief Science Officer
- AJ Bergmann, M.B.A., Chief Financial Officer
- Karen G. Krasney, J.D., Executive Vice President and General Counsel
- Mark Awadalla, Vice President of Clinical Operations
- Jonathan Tayco, Vice President of Program Management and Business Operations
- Minghao Sun, Ph.D., Vice President of Research and Product Development
- Yushi Feng, Ph.D., Vice President of Regulatory Affairs
- Frank Litvack M.D., FACC, Executive Chairman
- Paul G. Auwaerter, M.D., M.B.A., FIDSA, Director
- Earl M. (Duke) Collier Jr., Director
- George W. Dunbar, Jr., Director
- Philip J. Gotwals, Ph.D., Director
- Michael Kelliher, Director
- David B. Musket, Director
- Karimah Es Sabar, Director
Last updated: 2024-12-31
Mersana Therapeutics, Inc.
XMT-1592
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing antibody drug conjugates (ADC) for treating cancer patients with unmet needs. It specializes in ADC products like XMT-1592 and has strategic partnerships for the advancement of its innovative therapeutics.
Vision/Values | About | Directors | About | About | About | About | Contact | Contact | About | Careers | About | Culture | Benefits | Careers | Careers | Careers | Jobs | Jobs | Management | Careers | About | About | About | About
Symbol: MRSN
Recent Price: $1.42
Industry: Biotechnology
CEO: Dr. Martin H. Huber M.D.
Sector: Healthcare
Employees: 123
Address: 840 Memorial Drive, Cambridge, MA 02139
Phone: 617 498 0020
Leadership
- David Mott, Chairman of the Board
- Lawrence Alleva, Retired Partner, PriceWaterhouseCoopers
- Willard H. Dere, MD, Professor Emeritus of Internal Medicine, University of Utah
- Allene M. Diaz, Independent Commercial Strategy and Portfolio Management Consultant, AMD Consulting
- Andrew Hack MD, PhD, Managing Director, Bain Capital Life Sciences
- Kristen M. Hege, MD, Retired Senior Vice President, Early Clinical Development, Hematology/Oncology & Cell Therapy, Bristol Myers Squibb Company
- Anna Protopapas, Chair of the board of directors of Nuvalent
- Martin Huber, MD, President and Chief Executive Officer
Last updated: 2024-12-31
Syndax Pharmaceuticals, Inc.
SNDX-5613, SNDX-6352 (axatilimab), Entinostat
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer treatment, including innovative candidates like SNDX-5613 and SNDX-6352. It collaborates with notable institutions like the National Cancer Institute and has a license agreement with Kyowa Hakko Kirin Co., Ltd.
Symbol: SNDX
Recent Price: $12.52
Industry: Biotechnology
CEO: Mr. Michael A. Metzger M.B.A.
Sector: Healthcare
Employees: 184
Address: 35 Gatehouse Drive, Waltham, MA 02451
Phone: 781 419 1400
Last updated: 2024-12-31
Tyra Biosciences, Inc.
TYRA-300
Tyra Biosciences, Inc. is a preclinical-stage biopharmaceutical company focused on developing therapies to overcome tumor resistance and enhance outcomes for cancer patients. Its lead product candidate is TYRA-300, a selective inhibitor of FGFR3 for treating muscle invasive bladder cancer.
Symbol: TYRA
Recent Price: $13.90
Industry: Biotechnology
CEO: Dr. Todd Harris Ph.D.
Sector: Healthcare
Employees: 49
Address: 2656 State Street, Carlsbad, CA 92008
Phone: 619 728 4760
Last updated: 2024-12-31
Tonix Pharmaceuticals Holding Corp.
TNX-1500, TNX-2900, TNX-801, TNX-1840, TNX-1850, TNX-3500
Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company that focuses on developing therapies for immunology, rare diseases, infectious diseases, and central nervous system disorders. Key products include TNX-1500 for organ transplant and autoimmune diseases, TNX-2900 for Prader-Willi syndrome, and TNX-801 for smallpox prevention.
Symbol: TNXP
Recent Price: $0.36
Industry: Biotechnology
CEO: Dr. Seth Lederman M.D.
Sector: Healthcare
Employees: 103
Address: 26 Main Street, Chatham, NJ 07928
Phone: 862 799 8599
Last updated: 2024-12-31
Black Diamond Therapeutics, Inc.
BDTX-189, BDTX-1535, BDTX-4933
Black Diamond Therapeutics, Inc. is a biotechnology company that discovers, develops, and commercializes medicines for patients with genetically defined tumors. The company focuses on creating irreversible small molecule inhibitors to target specific oncogenic proteins.
Symbol: BDTX
Recent Price: $2.15
Industry: Biotechnology
CEO: Dr. Mark A. Velleca M.D., Ph.D.
Sector: Healthcare
Employees: 54
Address: One Main Street, Cambridge, MA 02142
Phone: 617 252 0848
Leadership
- Ali Behbahani, M.D., Co-Head of Healthcare, NEA
- Shannon Campbell, Executive Vice President and Chief Commercial Officer, Merus
- Kapil Dhingra, M.D., Former Head, Roche Oncology Development
- Samarth (Sam) Kulkarni, Ph.D., CEO, CRISPR Therapeutics AG
- Garry E. Menzel, Ph.D., Operating Partner, GHO Capital Partners LLP
- Prakash Raman, Ph.D., CEO of InduPro, Inc.
- Mark A. Velleca, M.D., Ph.D., CEO and Board Chair
Last updated: 2024-12-31
Compass Therapeutics, Inc.
CTX-009, CTX-471, CTX-8371
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing antibody-based therapeutics to treat various human diseases. Their clinical stage products include investigational bispecific antibodies like CTX-009 and monoclonal antibodies such as CTX-471.
Symbol: CMPX
Recent Price: $1.48
Industry: Biotechnology
CEO: Dr. Thomas J. Schuetz M.D., Ph.D.
Sector: Healthcare
Employees: 32
Address: 80 Guest Street, Boston, MA 02135
Phone: 617 500 8099
Last updated: 2024-12-31
Design Therapeutics, Inc.
Gene TAC
Design Therapeutics, Inc. is a preclinical-stage biopharmaceutical company developing therapies for genetic diseases caused by nucleotide repeat expansions. Their portfolio includes products targeting Friedreich Ataxia and Myotonic Dystrophy Type-1, as well as Gene TAC candidates for other similar diseases.
About | Contact | Careers | About | About | About | About | About | News | About | Careers | About
Symbol: DSGN
Recent Price: $6.17
Industry: Biotechnology
CEO: Mr. Pratik Shah Ph.D.
Sector: Healthcare
Employees: 57
Address: 6005 Hidden Valley Road, Carlsbad, CA 92011
Phone: 858 293 4900
Last updated: 2024-12-31
4D Molecular Therapeutics, Inc.
4D-125, 4D-110, 4D-310, 4D-150, 4D-710
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company developing product candidates using adeno-associated virus vectors, focusing on ophthalmology, cardiology, and pulmonology.
About | About | Contact | News | News | News | Careers | Careers | About | DEI | Careers | Leadership | Careers | Careers
Symbol: FDMT
Recent Price: $5.30
Industry: Biotechnology
CEO: Dr. David H. Kirn M.D.
Sector: Healthcare
Employees: 201
Address: 5858 Horton Street, EmeryVille, CA 94608
Phone: 510 505 2680
Last updated: 2024-12-31
PTC Therapeutics, Inc.
Translarna, Emflaza, Tegsedi, Waylivra, Evrysdi
PTC Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering, developing, and commercializing medicines for patients with rare disorders. The company offers a portfolio of products including treatments for Duchenne muscular dystrophy, rare diseases, and spinal muscular atrophy.
About | History | Leadership | About | Contact | Careers | Careers | Jobs | About | About | About | About
Symbol: PTCT
Recent Price: $45.77
Industry: Biotechnology
CEO: Dr. Matthew B. Klein F.A.C.S., M.D., M.S.
Sector: Healthcare
Employees: 988
Address: 100 Corporate Court, South Plainfield, NJ 07080
Phone: 908 222 7000
Leadership
- Matthew B. Klein, M.D., M.S., F.A.C.S., CEO, PTC Therapeutics, Inc.
- Neil Almstead, Ph.D., Chief Technical Operations Officer
- John Baird, Ph.D., Chief of Staff to the CEO
- Mark E. Boulding, Executive Vice President and Chief Legal Officer
- Lee Golden, M.D., Chief Medical Officer
- Pierre Gravier, Chief Financial Officer
- Mary Frances Harmon, Senior Vice President, Corporate and Patient Relations
- Linda Montella-Carter, Senior Vice President and Chief Information Officer
- Eric Pauwels, Chief Business Officer
- Hege Sollie-Zetlmayer, Chief Human Resources Officer
- Christine Utter, Senior Vice President, Chief Accounting Officer and Head of People Services
- Michael Schmertzler, Chairman
- William F. Bell, Jr., Managing Director and Head of Healthcare Services Practice, L.E.K. Consulting
- Allan Jacobson, Ph.D., University of Massachusetts Chan Medical School
- Stephanie S. Okey, M.S., Former SVP, Head of North America, Rare Disease – Genzyme
- Emma Reeve, Independent Board Director
- Mary Smith, The VENG Group
- David P. Southwell, Former CEO, TScan Therapeutics
- Glenn D. Steele, Jr., M.D., Ph.D., Chairman, GSteele Health Solutions
- Alethia Young, Chief Financial Officer, Bicycle Therapeutics
- Jerome B. Zeldis, M.D., Ph.D., Independent Board Director
Last updated: 2024-12-31
Relay Therapeutics, Inc.
RLY-4008, RLY-2608, RLY-1971
Relay Therapeutics, Inc. is a clinical-stage company that focuses on precision medicine in oncology and genetic diseases by transforming the drug discovery process. Their leading products include small molecule inhibitors for advanced cancer treatment.
Symbol: RLAY
Recent Price: $4.18
Industry: Biotechnology
CEO: Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS
Sector: Healthcare
Employees: 323
Address: 399 Binney Street, Cambridge, MA 02139
Phone: 617 370 8837
Last updated: 2024-12-31
TransCode Therapeutics, Inc.
TTX-MC138
Trans Code Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing drugs and diagnostics for treating metastatic disease. Their lead product, TTX-MC138, is aimed at metastatic cancer treatment, along with a range of other therapeutic platforms targeting cancer through innovative RNA- and CRISPR-based technologies.
Symbol: RNAZ
Recent Price: $3.76
Industry: Biotechnology
CEO: Mr. Thomas A. Fitzgerald M.B.A.
Sector: Healthcare
Employees: 10
Address: 6 Liberty Square, Boston, MA 02109
Phone: 857-837-3099
Last updated: 2024-12-31
Syros Pharmaceuticals, Inc.
Tamibarotene
Syros Pharmaceuticals is a biopharmaceutical company focused on developing treatments for cancer and monogenic diseases through gene control medicines. Key products include Tamibarotene for myelodysplastic syndrome and acute myeloid leukemia, and SY-5609 for advanced solid tumors.
About | Leadership | Directors | About | Contact | Careers | Vision/Values | DEI | Careers | About | About
Symbol: SYRS
Recent Price: $0.25
Industry: Biotechnology
CEO: Mr. Conley Chee
Sector: Healthcare
Employees: 68
Address: 35 CambridgePark Drive, Cambridge, MA 02140
Phone: 617 744 1340
Leadership
- Conley Chee, President and Chief Executive Officer
- Jason Haas, Chief Financial Officer
- Gerald E. Quirk, Chief Legal & Compliance Officer; Chief Business Officer
- Lisa Roberts, VP Human Resources
- David A. Roth, M.D., Chief Medical Officer
- Kristin Stephens, Chief Development Officer
Last updated: 2024-12-31
TRACON Pharmaceuticals, Inc.
therapeutics for cancer
TRACON Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing cancer therapeutics, including clinical stage products like envafolimab, YH001, TRC102, and TJ004309, with collaboration agreements with various biopharmaceutical companies.
Symbol: TCON
Recent Price: $0.03
Industry: Biotechnology
CEO: Mr. Craig R. Jalbert CIRA
Sector: Healthcare
Employees: 17
Address: 4350 La Jolla Village Drive, San Diego, CA 92122
Phone: 858 550 0780
Last updated: 2024-12-31
TScan Therapeutics, Inc.
T cell receptor-engineered T cell therapies
TScan Therapeutics, Inc. is a preclinical-stage biopharmaceutical company that develops T cell receptor-engineered T cell therapies for cancer treatment. It is working on therapies for hematologic malignancies and solid tumors, as well as vaccines for infectious diseases like SARS-CoV-2.
About | About | Management | Directors | About | About | Contact | Careers | Careers | Careers | About | About
Symbol: TCRX
Recent Price: $3.00
Industry: Biotechnology
CEO: Dr. Gavin MacBeath Ph.D.
Sector: Healthcare
Employees: 175
Address: 830 Winter Street, Waltham, MA 02451
Phone: 857 399 9500
Leadership
- Stephen Biggar, M.D., Ph.D., Partner at Baker Bros. Advisors LP
- Katina Dorton, J.D., M.B.A., CFO of Nodthera
- Gabriela Gruia, M.D., Chief Development Officer at Ichnos Sciences
- Barbara Klencke, M.D., Former Chief Medical Officer and Chief Development Officer of Sierra Oncology Inc.
- Gavin MacBeath, Ph.D., CEO of TSCAN
- Garry Nicholson, Former President of Pfizer Oncology
- R. Keith Woods, Former Chief Operating Officer of argenx
Last updated: 2024-12-31
Tempest Therapeutics, Inc.
TPST-1495, TPST-1120, TREX-1
Tempest Therapeutics Inc. is a clinical-stage oncology company developing small molecule therapeutics to treat cancer, with key programs in TPST-1495 and TPST-1120, and research in TREX-1 enzyme modulation.
Symbol: TPST
Recent Price: $0.84
Industry: Biotechnology
CEO: Mr. Stephen R. Brady J.D., LLM
Sector: Healthcare
Employees: 17
Address: 7000 Shoreline Court, South San Francisco, CA 94080
Phone: 415 798 8589
Last updated: 2024-12-31
vTv Therapeutics Inc.
TTP399
v Tv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing orally administered treatments for diabetes and other diseases. Key products include TTP399 for type 1 diabetes and HPP737 for inflammatory diseases.
Symbol: VTVT
Recent Price: $13.97
Industry: Biotechnology
CEO: Mr. Paul J. Sekhri M.Sc.
Sector: Healthcare
Employees: 16
Address: 3980 Premier Drive, High Point, NC 27265
Phone: 336 841 0300
Last updated: 2024-12-31
Xilio Therapeutics, Inc.
XTX101
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients with a focus on tumor-selective therapies.
Symbol: XLO
Recent Price: $0.97
Industry: Biotechnology
CEO: Dr. Rene Russo BCPS, Pharm.D.
Sector: Healthcare
Employees: 73
Address: 828 Winter Street, Waltham, MA 02451
Phone: 617 430 4680
Last updated: 2024-12-31
Tango Therapeutics, Inc.
TNG908
Tango Therapeutics, Inc. is a biotechnology company focused on discovering and developing drugs for cancer treatment, with a lead program TNG908 targeting cancers with methylthioadenosine phosphorylase deletions. The company also works on therapies for BRCA1/2-mutant and STK11-mutant cancers and collaborates with Gilead Sciences, Inc.
Symbol: TNGX
Recent Price: $3.10
Industry: Biotechnology
CEO: Dr. Barbara L. Weber M.D.
Sector: Healthcare
Employees: 140
Address: 100 Binney Street, Cambridge, MA 02142
Phone: 857 320 4900
Last updated: 2024-12-31
Ventyx Biosciences, Inc.
VTX958
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule product candidates for the treatment of inflammatory diseases and autoimmune disorders. Key products include VTX958 for immune-mediated diseases, VTX002 for ulcerative colitis, and VTX2735 for systemic inflammatory diseases.
Symbol: VTYX
Recent Price: $2.23
Industry: Biotechnology
CEO: Dr. Raju S. Mohan Ph.D.
Sector: Healthcare
Employees: 73
Address: 662 Encinitas Boulevard, Encinitas, CA 92024
Phone: 760 593 4832
Last updated: 2024-12-31